The 2025 Bexar County trial in Mendez v. Koozies Icehouse & Grill did more than produce an unprecedented $831 million TBI verdict—it reshaped how attorneys nationwide think about proving brain injury. While the case didn’t create appellate precedent, it set a powerful practical precedent that is already influencing litigation strategies, expert testimony, and settlement negotiations.
Back to Insights
Legal PrecedentMarch 2025
The Litigation Impact of Mendez v. Koozies Icehouse & Grill (Texas, 2025)
How a Catastrophic TBI Case Quietly Shifted the Use of Biomarkers in Courtrooms
$831MTBI Verdict
Key Findings
Six Ways Mendez Changed the Landscape
01
First Major Trial to Successfully Use a Full TBI Biomarker Panel
The plaintiffs presented three modern neurological biomarkers—GFAP, NfL, and p‑Tau 217—to quantify the massive brain damage suffered by Blas Mendez Jr. This was the first widely reported civil trial in the U.S. where a panel of biomarkers was admitted without challenge and placed front‑and‑center before a jury.
02
Biomarkers Made the Injury Visible
Jurors saw objective, quantitative proof of glial destruction (GFAP), widespread axonal injury (NfL), and ongoing neurodegeneration (p‑Tau 217). The biomarkers transformed what is usually abstract medical testimony into concrete, measurable damage. This “visibility” played a key role in the jury’s decision.
03
Admissibility Without a Daubert Fight
Although the case did not produce an appellate ruling, the trial court accepted GFAP, NfL, and p‑Tau 217 as scientifically reliable without issuing a contested Daubert opinion. This has reassured plaintiffs’ firms that these biomarkers can survive admissibility scrutiny—especially in severe TBI cases with strong clinical correlation.
04
A New Benchmark for TBI Valuation
The size of the verdict sent a clear message: objective biomarkers dramatically increase the perceived value of TBI claims. After the Mendez verdict, plaintiff firms began ordering biomarker panels earlier in cases, and insurers became more cautious about dismissing TBI complaints as “subjective” or “unprovable.”
05
Accelerated Acceptance of Emerging Science
p‑Tau 217, considered the most cutting‑edge of the three biomarkers, was admitted and used effectively. This has encouraged attorneys to consider biomarker evidence not only in severe cases but eventually in moderate or even mild TBIs.
06
A Practical, Not Appellate, Precedent
Though not binding case law, Mendez is being cited in Daubert briefs, referenced in demand letters, discussed in CLEs and conferences, and used as a strategic model for high‑value TBI litigation. In practice, it has become a go-to example of how biomarkers can anchor causation and damages in a way that neuropsych testing and imaging often cannot.
Bottom Line for Attorneys
Mendez signals a turning point: blood-based biomarkers are no longer “emerging science”—they are becoming standard tools for proving both the existence and severity of TBI in court.
Plaintiffs’ Attorneys Now Leverage Biomarkers To
- Validate TBI claims early
- Strengthen causation opinions
- Rebut defense arguments about normal imaging
- Support significantly higher damage models
Defense Attorneys Must Adapt
Defense attorneys must prepare for a future where challenging biomarker science requires more sophistication, not blanket skepticism.
The era of dismissing TBI claims based on “normal imaging” is ending. Biomarkers are filling the gap.
Want to Understand How This Applies to Your Cases?
NWP Healthcare provides the biomarker evidence system that powered the Mendez verdict. Contact us for a strategic briefing on how biomarker evidence can strengthen your litigation.
